Insights & Resources

Texas life sciences saw record capital in Q4 2025, even as innovation, early-stage funding and late-phase clinical trials continued to decline.

Leadership coaching helps executives perform with clarity, confidence and impact, especially during times of rapid change and uncertainty.

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

Explore ASC 805’s role in bringing clarity to business combinations — from fair value measurements to goodwill and beyond.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

Weaver’s Chief Talent Officer, Linc Ashby, gives his insights on those qualities of a leader that set both companies and teams up for success.

Due diligence is a crucial step in any merger and acquisition process. This can be especially challenging for Software-as-a-Service (SaaS) companies.

With an increasing demand for lithium across the energy sector, oilfields may find a common biproduct may hold the key to future growth.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

Whether preceding an M&A transaction or another executive hire, due diligence identifies any red flags before inking a high-stakes deal.

In a business sale, due diligence is critical to mitigate the risk of unexpected tax issues for buyers and sellers. Find out key components of tax due diligence.